Diabetes-induced microvascular complications at the level of the spinal cord; a contributing factor in diabetic neuropathic pain

***a,c N. Ved, ***a M.E. Da Vitoria Lobo, b S.M. Bestall, a C.L. Vidueira, b N. Beazley-Long, d K. Ballmer-Hofer, e M. Hirashima, a,g D.O. Bates, b L.F. Donaldson and a,f R.P. Hulse*

a Cancer Biology, Division of Cancer and Stem Cells, School of Medicine University of Nottingham, Nottingham NG7 2UH, b Arthritis Research UK Pain Centre and School of Life Sciences, The Medical School QMC, University of Nottingham, Nottingham NG7 2UH. c Institute of Ophthalmology, 11-43 Bath St, London EC1V 9EL, d Paul Scherer Institute, Villingen, Switzerland, e Division of Vascular Biology, Kobe University. f School of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS. g Centre of Membrane and Protein and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK.

*Corresponding author
**These authors contributed equally to this work

Corresponding Author Contact Details
Dr RP Hulse
Richard.Hulse@nottingham.ac.uk
School of Science and Technology
NHB 165
Nottingham Trent University
Clifton Lane
Nottingham
NG11 8NS

Richard.Hulse@ntu.ac.uk
Tel: 01158486368

This is an Accepted Article that has been peer-reviewed and approved for publication in the The Journal of Physiology, but has yet to undergo copy-editing and proof correction. Please cite this article as an 'Accepted Article'; doi: 10.1113/JP275067.

This article is protected by copyright. All rights reserved.
Abstract
Abnormalities of neurovascular interactions within the central nervous system of diabetic patients is associated with the onset of many neurological disease states. However, to date, the link between the neurovascular network within the spinal cord and regulation of nociception has not been investigated despite neuropathic pain being common in diabetes. We hypothesised that hyperglycaemia-induced endothelial degeneration in the spinal cord, due to suppression of VEGF-A/VEGFR2 signalling, induces diabetic neuropathic pain. Nociceptive pain behaviour was investigated in a chemically induced model of type 1 diabetes (streptozotocin induced, insulin supplemented; either vehicle or VEGF-A\textsubscript{165b}
treated) and an inducible endothelial knockdown of VEGFR2 (tamoxifen induced). Diabetic animals developed mechanical allodynia and heat hyperalgesia. This was associated with a reduction in the number of blood vessels and reduction in Evans blue extravasation in the lumbar spinal cord of diabetic animals versus age-matched controls. Endothelial markers occludin, CD31 and VE-cadherin were downregulated in the spinal cord of the diabetic group versus controls, as well as a concurrent reduction of VEGF-A_{165b} expression. In diabetic animals, VEGF-A_{165b} treatment (biweekly intraperitoneal, 20ng/g) restored normal Evans blue extravasation and prevented vascular degeneration, diabetes-induced central neuron activation and neuropathic pain. Inducible knockdown of VEGFR2 (tamoxifen treated $Tie2CreER^{T2}$-$vegfr2^{flfl}$ mice) led to a reduction in blood vessel network volume in the lumbar spinal cord and development of heat hyperalgesia. These findings indicate that hyperglycaemia leads to a reduction in the VEGF-A/VEGFR2 signalling cascade resulting in endothelial dysfunction in the spinal cord, which could be an undiscovered contributing factor to diabetic neuropathic pain.

Abbreviations
VEGF-A = vascular endothelial growth factor-A
VEGFR2 = vascular endothelial growth factor receptor 2
STZ = streptozotocin
i.p. = intra-peritoneal

Introduction
Diabetes mellitus leads to an array of health complications that can cause significant morbidity. In people with diabetes, neuropathic pain is common (Tesfaye et al., 2013), characterised by enhanced responses to noxious (painful) stimuli (hyperalgesia) as well as to innocuous stimuli (allodynia). These alterations in pain perception are due to maladaptive changes in the sensory neuronal circuitry. The plasticity of the nociceptive neuronal systems, both peripheral (Reichling & Levine, 2009) and central (Latremoliere A, 2009), means that they can respond to disease and/or treatment such as in diabetes (Chen & Levine, 2001) (Morgado et al., 2010; Tan et al., 2012). These responses lead to neuronal sensitisation, and in diabetes, chronic pain development. The peripheral sensory nerves are well known to be affected by hyperglycaemia, including degeneration of intra-epidermal nerve fibre innervation patterns (Hulse et al., 2015) and hyper-excitability (Chen & Levine, 2003). However, pain
management in people with diabetes often only provides partial pain relief (Tesfaye et al., 2011; Tesfaye et al., 2013). There are now focussed efforts to investigate how changes in nociceptive processing in the central nervous system, in particular the spinal cord, are altered in diabetic neuropathic pain (Biessels et al., 2014; Tesfaye et al., 2016). Studies have identified that in diabetic rodents, sensory neurons within the spinal cord elicit exaggerated responses to sensory stimulation (Morgado et al., 2010; Tan et al., 2012). Despite this evidence for the involvement of spinal cord changes in the pathogenesis of diabetic neuropathic pain, there are few investigations into those mechanisms that may underlie the development of central sensitisation in the spinal cord in diabetes (Tan et al., 2012; Lee-Kubli CA, 2013).

An important component of the nervous system is the supporting blood vessel network. A compromised vascular system is integral to the development of multiple neurological diseases (e.g. stroke, Alzheimer’s disease) (Tiehuis et al., 2008; Vandal et al., 2014; Winkler et al., 2015). Hyperglycaemia induces extensive vascular remodelling in the nervous system (Taylor et al., 2015; Hardigan et al., 2016) as well as direct glucose toxicity on sensory neurons (Chowdhury et al., 2014; Hulse et al., 2015), with both of these contributing to neurological complications including increased susceptibility of people with diabetes to cognitive decline, stroke, and peripheral ischaemic neuropathies (motor, sensory and autonomic) (Said, 2007; Hardigan et al., 2016). Vascular endothelial growth factor-A (VEGF-A) is strongly implicated in diabetic vascular disease, including driving aberrant vessel growth and increased permeability in diabetic retinopathy (Cai & Boulton, 2002). This is highly correlated with increased VEGF-A expression and is therefore a prime target for diabetic retinopathy treatment (Gupta et al., 2013). The VEGF-A gene gives rise to a variety of VEGF-A splice variants, differing in length and terminal sequence, leading to contrasting functions (Harper & Bates, 2008). The archetypal proangiogenic isoform is VEGF-A165a and is typically associated with vascular remodelling such as in diabetic retinopathy and cancer (Perrin et al., 2005). The VEGF-A165b isoform is predominantly found in normal tissues, areas with reduced angiogenesis (Pritchard-Jones et al., 2007), and pathologies where angiogenesis is impaired (e.g. systemic sclerosis and peripheral arterial disease) (Manetti et al., 2011; Kikuchi et al., 2014; Ngo et al., 2014). It is known to compete with VEGF-A165a for VEGFR2 binding (Bates et al., 2002; Cébe Suarez S, 2006) and can independently act through VEGFR2, resulting in cytoprotective effects (Beazley-Long et al., 2013). For example, in diabetic nephropathy VEGF-A165b treatment leads to a rescue in endothelial cell...
survival and return to normal kidney function (Oltean et al., 2014), and we have previously found that indicators of altered blood vascular integrity, enhanced in the peripheral nervous system and the dorsal root ganglia, can be reversed by VEGF-A_{165b}, resulting in amelioration of pain behaviours in rats (Hulse et al., 2015).

Enhanced sensitivity in central nociceptive networks (spinal cord (Tan et al., 2012; Lee-Kubli CA, 2013), brain (Silva M, 2013)) have long been attributed to neuroplastic changes. Despite extensive evidence that the cerebral vasculature is altered in diabetic rodents, there has been limited investigation into the neurovascular interactions in the spinal cord particularly with reference to nociception (Costigan et al., 2009; Beggs et al., 2010). Here we hypothesised that a decline (endothelial cell loss) in the vascular system within the spinal cord could contribute to the onset of diabetic neuropathic pain. Using an in vivo rat model of type 1 diabetes, and an inducible VEGF receptor-2 (VEGFR2) knockdown transgenic mouse, neuro-vascular disruption in the spinal cord was associated with changes in neuropathic pain. Administration of the VEGF-A_{165b} isoform protected the endothelial component of the CNS, and prevented diabetic neuropathic pain.

Methods

**Ethical Approval, Animals used and Diabetes induction**

24 male (21 Evans blue and 3 S1 tissue collection) and 42 female (24 Evans blue and 18 S1 tissue collection) Sprague Dawley rats (~250g) were used in this study. Experiments were carried out in accord with the institution’s animal welfare committee (UoN), and conform to the principles and regulations as described in the Editorial by Grundy (Grundy, 2015). Procedures were carried out in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986 and EU Directive 2010/63/EU after review by the local Animal Welfare and Ethics Review Board (UoN). Diabetes was induced by intraperitoneal (i.p.) injection of streptozotocin (STZ) (50mg/kg)(Hulse et al., 2015). Animals had ad libitum access to standard chow and were housed in groups (n>2) under 12:12h light:dark conditions. In male rats, experimental groups (1 week, no insulin supplementation) were naïve (sham injected n=9) and STZ treated (n=12). At the end of the study animal weight and blood glucose (>15mmol) were naïve=339±8.26g and 6.8±0.85 mmol; diabetics=314±11.86g and 30.12±0.95 mmol respectively.
In female rats (8 week experiments), animals were treated with insulin using one third of an insulin pellet (Linshin, Canada) implanted under isoflurane anaesthesia (2-3% in O₂) (Calcutt, 2004). Experimental treatments were biweekly recombinant human (rh)VEGF-A₁₆₅b (20ng/g body weight, i.p. twice weekly from week 1) or saline (vehicle; i.p.). This VEGF-A₁₆₅b regime has previously been used (Beazley-Long et al., 2013; Hulse et al., 2014)). Blood glucose and weight was measured in all animals at the end of the study. Blood glucose: naïve=8.08±0.72, diabetic+vehicle=29.27±1.35, diabetic+VEGF-A₁₆₅b=30.81±0.78. Animal body weight: naïve=324.1g±8.5, diabetic+vehicle=284.2±7.3g, diabetic+VEGF-A₁₆₅b=289.1±5.4g.

75 transgenic mice were used in this study(C57.bl6,25-30g; both genders). Tie2CreER<sup>T2</sup> mice [Tg(Tek-cre/ER<sup>T2</sup>)1Arnd, European Mutant Mouse Archive] were crossed with vegfr2<sup>fl/fl</sup> (generated/used as previously described (Albuquerque et al., 2009; Sison et al., 2010; Beazley-Long et al., 2018)). All mice used were vegfr2<sup>fl/fl</sup> and either Tie2CreER<sup>T2</sup> positive (n=27) or Tie2CreER<sup>T2</sup> negative (n=28) and dosed once daily by i.p. with 1mg tamoxifen or vehicle (10% ethanol in sunflower oil) for 5 consecutive days.

**Nociceptive Behaviour**

Nociceptive behavioural experiments were carried out as previously described (Drake et al., 2014; Hulse et al., 2016). on 8 week diabetic animals and age matched sham controls (naïve). Mechanical withdrawal thresholds were measured using von Frey (vF) monofilaments (Hulse et al., 2015) or a mechanical pincher (Drake et al., 2014; Hirschberg et al., 2017). A range of von Frey hairs were applied to the hind paw plantar surface (a maximum of five seconds or until paw withdrawal). A total of five vF applications were applied per weighted hair and force response curves were generated and withdrawal values were calculated as the weight at which withdrawal frequency = 50%. A mechanical pincher (equipped with strain gauges and calibrated to force (g)) (Drake et al., 2014) was applied to the hind paw until the animal withdrew to determine mechanical hyperalgesia. Raw data were acquired through a Neurolog power unit and a bridge amp module (Digitimer), with digital acquisition via CED micro1401v3 and Spike2 v7 software (Cambridge Electronic Design UK). Withdrawal to heat was determined using the Hargreaves test (Hargreaves et al., 1988). The experimenter was blinded to treatment.
Evans blue extravasation

In vivo vascular perfusion was evaluated using Evans blue dye, as previously described (Xu et al., 2001). Animals (age matched sham controls (naïve), week 1 and week 8 diabetic rats) were terminally anesthetized (ketamine medetomidine i.v. 50 mg/kg) and infused (via the external jugular vein) with Evans blue dye i.v. (Sigma-Aldrich, 45 mg/kg) at 120mmHg pressure. Two minutes post-infusion, 0.2mL arterial blood was withdrawn, followed by subsequent 0.1mL withdrawals every 15 minutes for 2 hours. After 2 hours 0.2mL blood was withdrawn followed by cardiac perfusion of 50mL saline at 120mmHg. Lumbar spinal cord and a single brain hemisphere were excised (whole spinal cord including ventral and dorsal horn) and weighed (wet weight). Tissue was dried at 70°C overnight and weighed (dry weight). Dried tissue was incubated in 0.15mL formamide (Sigma Aldrich) at 70°C overnight. Blood samples were centrifuged (12,000rpm, 45 minutes, 4°C), and the supernatant from tissue and blood samples were analysed at 620nm. Evans blue extravasation was calculated as (solute flux (μg/min/g) = Evans blue mass (μg)/ tissue dry weight (g) divided by time (120min).

Immunofluorescence analyses

Animals from all experimental groups (normal, diabetes, diabetes+VEGF-A165b; 8 weeks) were terminally anaesthetised (sodium pentobarbital 60mg/kg i.p.) and transcardially perfused, with phosphate buffered saline (PBS) followed by 4% paraformaldehyde in PBS (PFA; pH7.4). Tissue was prepared as previously described (Hulse et al., 2016). Spinal cords (40µm thickness) were incubated in primary antibodies (see below) in blocking solution (5% bovine serum albumin, 10% fetal calf serum), overnight at 4°C (IB4 72 hours). Primary antibodies/markers and dilutions used were: biotin conjugated isolectin B4 (IB4; 1 in 100, Sigma-Aldrich); rat anti-CD31 (MEC13.3; 1 in 10, Santa Cruz), mouse anti-CD31 (1 in 100, Abcam), rabbit anti-GFAP (1 in 500, Abcam), rabbit anti-fos (1 in 100, Santa Cruz); mouse anti-NeuN (1 in 200; Millipore), rabbit anti-VEGFR2 (1 in 200, 55B11, Cell Signalling), rabbit anti-cleaved caspase 3 (1 in 500, Cell Signalling) and anti-rabbit biotinylated IgG (1 in 500, Jackson Laboratories). Secondary antibodies were incubated in PBS + 0.2% Triton X-100, which were Alexa Fluor 488-conjugated chicken anti-mouse, Alexa Fluor 555-conjugated donkey anti-rabbit and streptavidin-conjugated Alexa Fluor-555 (1 in 500, all Invitrogen, UK. Confocal imaging of the dorsal horn of the lumbar spinal cord of all groups was performed on a Leica TCS SPE confocal microscope.

This article is protected by copyright. All rights reserved.
Spinal cord Endothelial Cell Culture

Whole lumbar spinal cords were dissected from adult male Sprague Dawley rats and dissociated (0.125% collagenase). Endothelial cells were extracted and cultured in endothelial media (M199 media, 60μg/ml endothelial cell growth supplement and 50μg/ml Heparin). Endothelial cells were plated (1% gelatin coated) onto either 6 well plates (for protein extraction) or 96 well plates (for cell viability studies). For cell viability assays, when 80% confluent endothelial cells were incubated for 24 hours in either 5mM glucose (normal), 50mM mannitol (osmotic control) or 50mM glucose (high glucose) + 2.5nM VEGF-A165b or vehicle. Cell death was determined with neutral red (Sigma-Aldrich).

Flow Cytometry

Spleens were isolated from CTL and ecKO transgenic mouse experimental groups and placed in media (containing RPMI1640, Penicillin/streptomycin, 10% FBS, 1%I-glutamine, 0.1% sodium pyruvate). Tissue was mechanically dissociated through a 40μm cell strainer and washed through with media. Cell suspension was then centrifuged at 1500rpm for 3mins. Supernatant was removed and cells were resuspended in 2 ml red cell lysis medium (Sigma), then left for 30 seconds. Following this 10ml of media was added and the cells were centrifuged as previously. Cells were then fixed in 4% paraformaldehyde for 15minutes at room temperature and then subsequently washed three times. Cells were permeabilised with 0.4% Triton X-100 in PBS for 15 minute at room temperature. Cells were blocked in 1% FBS in PBS, mixed gently and incubated for 30 min at room temperature. Antibodies (CD11b-APC (1 in 100; Biolegend) and F4/80-PE (1 in 100; Biolegend)) were added, left overnight in the fridge, and samples analysed on MoFlo analyser.

qPCR Method

Total RNA was extracted from whole lumbar spinal cord tissue isolated from CTL and ecKO transgenic colony experimental groups using TRIzol reagent (Invitrogen). cDNA synthesis was carried using PrimeScript™RT reagent kit (TaKaRa,RR037A) with a starting amount of 1μg of RNA. The resulting cDNA was used for Q-PCR using a LightCycler 480 SYBR Green I Mastermix (Roche 04707516001) following the manufacturer’s instructions. CD31 and VECadherin primers were synthesised by Eurofins. Beta actin and VEGFR2 primers were
synthesised by Sigma-Aldrich. Beta actin was used as a reference gene. The primer sequences were as follows (5’-3’);

\[
\beta\text{-actin } F \rightarrow 5' \text{ ATTGCCAATGAGCGGTTC } 3' \\
\beta\text{-actin } R \rightarrow 5' \text{ GGATGCCACAGGACTCCA-3'} \\
\text{CD31 } F \rightarrow 5' \text{ GAAATGCTCTCGAAGCCCAG } 3' \\
\text{CD31 } R \rightarrow 5' \text{ ACCTCGAGAGTCTGGAAGTC } 3' \\
\text{VE\text{-cadherin } } F \rightarrow 5' \text{ TCCCTGGACTATGAAGTCAT } 3' \\
\text{VE\text{-cadherin } } R \rightarrow 5' \text{ GAAGACAGGGGGCTCATCCA } 3' \\
\text{VEGFR2 } F \rightarrow 5' \text{ GGATCTGAAAAGACGCTTGG } 3' \\
\text{VEGFR2 } R \rightarrow 5' \text{ TGCTCCAAGGTCAGGAAGTC } 3' \\
\]

**Western Blotting**

Protein was extracted from spinal cord endothelial cells and human umbilical vein endothelial cells as well as spinal cord tissue as previously described (Vencappa et al., 2015; Hulse et al., 2016). Animals from all experimental groups (CTL and ecKO transgenic mice; normal, diabetes, diabetes+VEGF-A165b; 8 weeks) were terminally anaesthetised with sodium pentobarbital (i.p. 60 mg/kg, Sigma-Aldrich). Lumbar spinal cords were extracted, frozen immediately and stored at -80°C until sample processing. 100µg endothelial cell lysate and 80µg of each spinal cord lysates were loaded in a 4%-20% precast Mini-Protein TGX gel (Biorad), separated by SDS-PAGE electrophoresis and transferred using Trans-blot turbo transfer system (Bio-Rad). The membrane was incubated in 5% milk powder in tris-buffered saline (TBS)-TWEEN 0.1% (TBST) for 30 minutes at room temperature. Primary antibodies, mouse anti-CD31 (2µg/ml, Abcam; AB24590), rabbit anti-occludin (5µg/ml, Invitrogen; 71-1500), mouse anti-VE cadherin (5µg/ml, BD Biosciences; 550548), rabbit anti-VEGFR2 (1 in 200, 55B11, Cell Signalling), rabbit anti-Pan VEGF-A (A20, 1µg/ml, Santa Cruz; sc-152), mouse anti-VEGF-A165b (2µg/ml, Abcam; ab-14994), and rabbit anti-Actin (1:100 Santa Cruz) antibodies were diluted in blocking solution and incubated overnight at 4°C. Secondary antibodies (Licor donkey anti-rabbit and anti-mouse antibodies 1:10000) in TBST-0.1% 1% BSA and visualised on the Licor Odessey.

**Statistical Analysis**

All data are represented as mean±SEM unless stated and experimenter was blinded where appropriate. Data were acquired/quantified using Microsoft Excel 2010, Graphpad Prism 6
and Imaris (Bitplane) Spike2 v7 software (CED) was used to digitally acquire mechanical withdrawal thresholds from the pincher and for offline analysis. Immunofluorescence was quantified by obtaining 10 random non-sequential sections (Z stacks) per animal and a mean value calculated per animal. Dorsal horn spinal cords (Lamina I-V) were imaged with the confocal as described above, and vessels were identified through CD31 and IB₄ immunoreactivity. IB₄ signal fluorescence was vascular in the majority of the spinal cord with C-fibre projections also staining in the peripheral laminae (I-II), but vessels could also be clearly delineated here by CD31 staining as well as morphology. Stained images were rendered on Imaris 8.11 imaging software. This allows for automated quantification of vessel diameter and blood vessel volume. Neuron number (cleaved caspase-3 and C-Fos quantification) was determined as per laminae of the dorsal horn and therefore expressed according to lamina I-V as previously characterised (Hsieh et al., 2015). Western blot densitometry was quantified using ImageJ (https://imagej.nih.gov/ij/) gel quantification plugin. Paw mechanical withdrawal thresholds, the number of blood vessels in the dorsal horn of the spinal cord and spinal cord Evans blue extravasation were analysed using a Mann-Whitney test. Evans blue, IB₄ positive blood vessel volume and length, mechanical and heat nociceptive behaviour and western blot densitometry quantification were analysed using a Kruskal Wallis and appropriate post-hoc tests.

Results

Diabetes resulted in increased mechanical hyperalgesia - a reduction in withdrawal threshold to a noxious stimulus (hindpaw pinch) when compared to both before diabetes (p<0.05) and to vehicle/age matched animals at week 8 post STZ injection (naïve; Fig. 1A, *p<0.05). This was accompanied by a reduction in the number of blood vessels in the dorsal horn of the lumbar region of the spinal cord (Fig. 1B-D, *p<0.05) as well as a reduction in microvessel diameter (labelled with CD31 and IB₄) (Fig. 1E-G). The VEGF-A family is a key regulator of angiogenic processes. Pan-VEGF-A expression was unaltered in the lumbar spinal cord of diabetic rats when compared to age/gender matched control animals (Fig. 1H&I). However, VEGF-A₁₆₅b expression was significantly reduced in the lumbar spinal cord of diabetic animals (Fig. 1H, I, *p<0.05).

As hyperglycaemia affected spinal cord microvasculature and reduced VEGF-A₁₆₅b expression, we investigated the direct cytoprotective actions of VEGF-A₁₆₅b upon cultured spinal cord endothelial cells. Isolated spinal cord endothelial cells showed increased cell...
death when cultured in high (50mM) versus low glucose (5mM) conditions (Fig. 2A). There
was no effect of 50mM mannitol, an osmotic control. VEGF-A_{165}b treatment prevented high
glucose-induced endothelial cell death (Fig. 2A). Consequently, the cytoprotective actions of
VEGF-A_{165}b on the spinal cord endothelium were investigated \textit{in vivo}. The vascular network
was well defined in naïve animals (Fig. 2B), was reduced in number in diabetic+vehicle
treated animals (Fig. 2C) but this was prevented by VEGF-A_{165}b (Fig. 2D). Quantification
indicated a reduction in endothelium (reduced total vascular volume) within the dorsal horn
of the lumbar region of the spinal cord, which was rescued by VEGF-A_{165}b (Fig. 2E). There
was also an overall reduction in dorsal horn vessel diameter, again prevented by VEGF-
A_{165}b (Fig. 2F). There was a non-significant increase in vessel diameter in the
diabetic+VEGF-A_{165}b treated group when compared with the naïve group (Fig. 2F). Analysis
of the frequency distribution of the vessels by size indicated that the reduction in size in the
diabetics was due to a reduced number of the “larger microvessels” (8-12µm) rather than a
reduction in the number of small (<8µm vessels). (Fig. 2G). To determine whether markers
of endothelial integrity/activation (including junctional markers) were altered in the lumbar
spinal cord in diabetes, lumbar spinal cord protein samples were subjected to
immunoblotting for VE-cadherin (Fig. 3A upper band), CD31 (Fig. 3A lower band), and
occludin (Fig. 3B upper band; lower band actin). There was a marked reduction in junctional
and adhesion molecules in diabetic+vehicle treated rats, with non-significant reductions in
VE-cadherin (Fig. 3C) and significant reductions in CD31 (Fig. 3D) and occludin (Fig. 3E), all
of which were prevented by VEGF-A_{165}b treatment.

To investigate the possible functional changes in the microvasculature within the spinal cord
in diabetes, Evans blue extravasation was measured (Xu et al., 2001). Evans blue vascular
leakage is dependent on blood flow, surface area, hydrostatic pressure and vascular
permeability. In an acute diabetic rodent model (1 week) there was a pronounced decrease
in Evans blue extravasation within the lumbar region of the spinal cord compared with that of
the control cohort (Fig. 4A). Diabetic groups were systemically (i.p.) treated with either saline
or VEGF-A_{165}b (20ng/g) using a longer term diabetic model (8 weeks). In longer duration
diabetes (8 weeks) there was also a significant reduction in Evans blue extravasation
compared with the control naïve group (Fig. 4B), which was prevented by VEGF-A_{165}b (Fig.
4B). Brains were also extracted from the long term (8 week) study (Fig. 4C) though there
was no difference in solute flux between groups.
Mechanical hypersensitivity and heat hyperalgesia developed only in the diabetic+vehicle animals. VEGF-A$_{165}$b treatment (timepoint of administration shown via arrow) not only prevented the spinal cord vascular degeneration (consistent with previous experiments (Hulse et al., 2015; Ved et al., 2017)) but also prevented diabetic neuropathic pain behaviours (mechanical allodynia Fig. 5A and heat hyperalgesia Fig. 5B). Within the spinal cord, not only was the vasculature disturbed in the diabetic+vehicle group, but sensory neurons (NeuN) in the dorsal horn also expressed increased cleaved caspase-3 (CC3), an indicator of neuronal damage, when compared with naïve age matched animals (Fig. 5C). There was increased CC3 immunoreactivity in the superficial lamina (I & II) of the dorsal horn of diabetic animals (Fig. 5D). This was blocked by VEGF-A$_{165}$b treatment (Fig. 5E&F-D). Sensory neurons within the spinal cord, once activated, express the immediate early gene c-fos (Hunt SP, 1987). C-fos is a marker of neuronal activation in chronic pain states (Kalynovska et al., 2017; Khasabov et al., 2017) and is an indicator of spinal neuronal activation in diabetic neuropathic pain (Morgado et al., 2010). There was an increase in c-fos expression in neurons (NeuN co-labelled) within the lumbar dorsal horn in the spinal cord in diabetic rats (Fig. 6A&B) compared with naïve animals. Systemic treatment with VEGF-A$_{165}$b led to an attenuation of the diabetes induced c-fos expression (Fig. 6A&B). All lamina of the dorsal horn demonstrated increased c-fos expression in neurons in the diabetic+vehicle group compared with the naïve and diabetic+VEGF-A$_{165}$b groups (Fig. 6C).

The involvement of VEGF-A/VEGFR2 signalling on spinal cord endothelial cell function and survival and the relationship to the generation of behavioural hypersensitivity was determined by using an endothelial cell specific inducible VEGFR2 knockdown in vivo. Systemic tamoxifen treatment led to a reduction in VEGFR2 protein expression in endothelial cells from vegfr2$^{fl}$ Tie2CreER$^{T2}$-positive mice, i.e. VEGFR2 endothelial cell knockout (VEGFR2$^{ECKO}$) compared with control mouse endothelial cells (CTL = vegfr2$^{fl}$ Tie2CreER$^{T2}$-negative + tamoxifen) isolated from lung (Fig. 7A-B), as well as a reduction in VE-cadherin expression (Fig. 7C-D). In the spinal cord there was a reduction in VEGFR2 (Fig. 7E) as well as VE-cadherin (Fig. 7F) and CD31 (Fig. 7G) expression in the VEGFR2$^{ECKO}$ animals compared with CTL animals. In addition, VE-cadherin protein expression from the spinal cord of VEGFR2$^{ECKO}$ animals was reduced when compared with the CTL animals (Fig. 7H, I).

This article is protected by copyright. All rights reserved.
When compared with CTL mice (Fig. 8A-C), the VEGFR2ECKO (Fig. 8A; low power, 8B high power) had a significant decline in vascular integrity within the lumbar spinal cord 8 days after the final drug injection. The endothelium demonstrated a reduced endothelial volume (Fig. 8C) as well as showing a reduced diameter of spinal cord microvessels in the VEGFR2ECKO mice treated with tamoxifen when compared with CTL mice (and VEGFR2fl/fl with Cre but not given tamoxifen “vehicle”) (Fig. 8D). There was an increase number of smaller vessels in the VEGFR2ECKO mice when compared to control mice (CTL and vehicle) (Fig. 8E).

In VEGFR2ECKO and CTL mice there was no difference in nociceptive behaviour prior to tamoxifen administration (Fig. 8F). The vegfr2fl/fl Tie2CreERT2 mice treated with vehicle (“vehicle”) and CTL mice treated with either vehicle or tamoxifen demonstrated no change in nociceptive behavioural responses to heat (Fig. 8F). However, the VEGFR2ECKO mice demonstrated a pronounced heat hypersensitivity compared with all other groups following tamoxifen injection (Fig. 8I). To exclude the involvement of a subset of haemopoietic cells that express Tie2 and VEGFR2 we determined the impact of VEGFR2 knockdown in this cell population. There was no change in the number of F4/80 (macrophage marker) or CD11b marker of leukocytes including monocytes, neutrophils, natural killer cells, granulocytes and macrophages) positive cell types isolated from the spleen in either the CTL mice treated with tamoxifen or VEGFR2ECKO mice (Fig. 9).

Discussion

We show here that the microvasculature in the spinal cord was disrupted in a rodent model of diabetic neuropathic pain, demonstrated by a reduction in the volume of the blood vessel network in the spinal cord. These findings are associated with neuropathic pain development and spinal neuronal activation. There was a concurrent reduction in the spinal cord expression of the VEGF-A165b isoform, but no overall change in total VEGF-A expression. In the inducible VEGFR2ECKO mice, the vasculature in the lumbar spinal cord was also reduced and was accompanied by the development of hyperalgesia. Critically, reversing the diabetes-induced vascular degeneration using systemic VEGF-A165b treatment also resulted in reversal of chronic pain.
Neuropathic pain is common in diabetic patients and is typically associated with hyperglycaemia impacting upon the peripheral vasculature through alterations in blood flow and solute leakage (Poduslo & Curran, 1992; Tesfaye et al., 2013; Hulse et al., 2015). The peripheral sensory nerves are compromised in these instances through a degeneration of nerve terminals (loss of intra epidermal nerve fibre innervation) in the skin (Narayanaswamy et al., 2012), atrophy of the nerve trunk (shrinkage of nerve fibre diameter) (Hulse et al., 2015), reduction in nerve conduction velocity (Ali et al., 2014) and excitation of C nociceptor fibres (Chen & Levine, 2001). However, despite these widely diagnosed symptoms, current treatments have poor success rates and low long-term success. Recent advances in understanding diabetic pain have highlighted that neuropathic pain is associated with activation and alteration of nociceptive processing in the central nervous system. The spinal cord (Morgado et al., 2010) and brain (Silva M, 2013) are hyperactivated in rodent models of diabetic neuropathic pain, with increased activity of spinal wide dynamic range neurons (Pertovaara et al., 2001; Morgado et al., 2010; Tan et al., 2012). Microvascular degeneration is disrupted in the brain of diabetic rodents and linked to e.g. cognitive impairment (Taylor et al., 2015; Hardigan et al., 2016), however the impact of hyperglycaemia on the spinal cord microvasculature has not been reported previously. The results we present here support the conclusion that there is a widespread vasculopathy in the spinal cord, which is associated with diabetes and nociceptive processing. The reduced spinal vasculature associated with hyperglycaemia could be in part due to an increase in endothelial cell death. This compromises the function of the spinal cord microcirculation – to provide delivery of solutes as well as appropriate endothelial cell signalling – evidenced by altered neuronal activation (c-fos staining) in all five lamina of the dorsal horn, and caspase staining in laminae 1-2. Whether the effect on sensory neuronal function within the spinal cord is impaired as a result of decreased nutrient/oxygen delivery or through disturbance of an endothelial-neuronal-glial signalling event remains to be determined.

Multiple diabetic complications arise due to vascular pathology whereby vessel or cell function is impaired (e.g. retinopathy, nephropathy) (Gupta et al., 2013; Oltean et al., 2014). We have previously shown that enhanced extravasation in diabetes does occur in the peripheral nervous system, including in the DRG, and this is mediated in part through VEGF-A, as treatment with VEGF-A_{165b} – which can inhibit endogenous VEGF-A_{165b} signalling through VEGFR2, and prevent TRPA1 and TRPV1 activation in cultured DRG cells ex vivo, blocked the enhanced extravasation and the associated pain behaviours. In this case we
describe a reduction in solute flux in the CNS, which combined with a loss of vessels, can only be attributed to a reduction in blood flow. Evans blue extravasation is often taken as an indication of increased vascular permeability, and if blood is still flowing to the vessels where the vascular permeability increases, this is often consistent with the data. However, extravasation requires a provision of solute in the blood, and therefore is highly dependent on blood flow. A reduction in Evans blue extravasation in the spinal cord, where the permeability is already very low compared with most tissues (e.g. heart, skin, DRG (Hulse et al., 2015)), can only be reasonably interpreted as an indication of reduced surface area for exchange, or reduced capillary pressure. The loss of endothelial cell staining, reduction of CD31 combined with reduced Evans blue extravasation indicates that diabetic animals have lost functional blood vessels from the spinal cord. This is an interesting comparison with most other vascular beds (including eyes (Ved et al., 2017) and the peripheral nerves (Hulse et al., 2015)), where diabetes results in increased solute flux, probably through increased vascular permeability (Poduslo & Curran, 1992). In peripheral tissues such as in the sensory nerve and the DRG, increased blood-nerve barrier breakdown could arise due to direct glucose toxicity upon the vessels in the epineurium. However, sensory nerves are activated following exposure to high blood glucose (Chen & Levine, 2001; Chen & Levine, 2003). Such activity would drive peripheral extravasation through release of CGRP or activation of TRPA1; which is activated in sensory nerves of diabetic rodents (Koivisto et al., 2012; Hulse et al., 2015). These systems are not expected to be in play in the spinal cord therefore alternative mechanisms must be in action.

In this study we find that alterations in VEGF-A/VEGFR2 activation, as evidenced both by inhibition of VEGFR2 by VEGF-A_{165}b (Bates et al., 2002; Cébe Suarez S, 2006) and VEGFR2 knockout, is culpable in the decline in microvascular function. The VEGF-A family consists of two families of alternative spliced isoforms termed VEGF-A_{xxx}a and VEGF-A_{xxx}b (xxx denote amino acid number). These isoforms differ solely due to exon 8 splicing giving rise to differing C terminus sequences that critically alter isoform function (Harper & Bates, 2008). It has been shown that both bind to VEGFR2 with equal affinity and both possess cytoprotective actions, however VEGF-A_{xxx}a is pro-angiogenic and VEGF-A_{xxx}b is able to inhibit VEGF-A_{xxx}a mediated angiogenesis (Woolard et al., 2004). Therefore VEGF-A_{165}b (acting via VEGFR2) may act as a vascular protective agent under normal conditions, preventing loss of blood vessels. Loss of VEGF-A_{165}b in diabetic spinal cord removes such protection, resulting in vascular damage; reducing both vascular integrity and function. This
concept, that loss of endogenous endothelial cell VEGFR2 mediated cytoprotection contributes to nociceptive processing, is consistent with the results from the endothelial specific VEGFR2 KO mice. These mice demonstrated loss of spinal cord endothelium and associated development of hyperalgesia, consistent with this concept that endogenous maintenance of VEGFR2 activity is cytoprotective to the spinal cord endothelium, albeit that we have not directly measured spinal cord neuronal nociceptive processing. One interesting difference between the diabetic and VEGFR$^{\text{ECKO}}_2$ animals was that whereas the diabetic rats had a reduction in larger microvessels and no change in smaller vessels, the VEGFR$^{\text{ECKO}}_2$ animals had increased number of small but reduced numbers of larger vessels. This suggests that in diabetes the loss of vessels was due to either selective loss of larger microvessels (8-12µm), or a combination of loss of all vessels and a reduction in size of the larger vessels (hypotrophy or atrophy, or vasoconstriction). In contrast the VEGFR$^{\text{ECKO}}_2$ mice had the latter effect. The functional implications would still be ischemia, but may have other subtle differences in nutrient or cell delivery. While the understanding of spinal nociceptive neuronal processing in diabetes is progressing, the contribution of microvascular alteration has never been investigated in this context. Furthermore, it has been shown that peripheral sensory neurons become sensitised upon reduced perfusion (So et al., 2016), leading us to speculate that the changes in the spinal cord vascular network, as a result of hyperglycaemia that we report, could alter the microenvironment of the spinal cord sensory neurons and thus alter their level of activation. This would be anticipated to contribute to changes in pain perception and underlie neuropathic pain development.

The VEGFR2 knockdown was restricted to Tie2-positive cell types, which encompass the endothelial and haemopoietic cell populations. The Tie2 promoter driven transgenic models are widely used to investigate endothelial function (Makino et al., 2014; Moyes et al., 2014), however it has been reported that Tie2 is expressed on CD11b/CD45 positive cells. (De Palma et al., 2005; Tang et al., 2010). In this study there was no impact of VEGFR2 knockout on haematopoietic cell populations. An impact of this knockout system on circulatory macrophages and consequent endothelium would be expected to be minimal as there is a very small number of, if any, Tie2-positive, VEGFR2 positive macrophages (Okubo et al., 2016).

People with diabetes are susceptible to neurological disease as a result of the microvascular dysfunction, impacting on motor, autonomic and cognitive systems, and increased
susceptibility to stroke and dementia (Kissela et al., 2005; Tiehuis et al., 2008). The VEGF-A angiogenic family has a pivotal role in managing vascular development and function (Bates, 2010), however additional evidence now also supports a fundamental role for this family in neuronal activity and survival (Verheyen et al., 2012; Beazley-Long et al., 2013). As a consequence, VEGF-A treatment has been trialled for peripheral diabetic neuropathy (Schratzberger et al., 2001; Ropper et al., 2009). Experimental hyperglycaemia leads to a reduction in VEGF-A and VEGFR2 expression in the brain; VEGF-A treatment can protect both endothelium and neuronal circuits (Taylor et al., 2015). Dysfunction of the VEGF-A signalling pathway within the hippocampus impacts upon the microvasculature and leads to impaired spatial memory (Reeson et al., 2015; Taylor et al., 2015). A decline in vascular support and diminished vascular response in diabetes and stroke models therefore clearly affects neuronal function. However, VEGF-A_{165}a also increases vascular permeability and stimulates abnormal angiogenesis, which is detrimental in the CNS, for instance in diabetic retinopathy (Perrin et al., 2005). The VEGF-A_{xxxb} isoforms, however, do not stimulate angiogenesis or increase solute flux in diabetes, in fact they can reverse it in rodent models of diabetic retinopathy (Ved et al., 2017). Despite these opposing profiles both families are cytoprotective, for endothelial cells and neurons (Beazley-Long et al., 2013; Oltean et al., 2014; Hulse et al., 2015; Vencappa et al., 2015). For example, reduced VEGF-A_{165}b expression in diabetic patients is associated with reduced kidney function (Oltean et al., 2014). Furthermore, treatment of diabetic mice with VEGF-A_{165}b prevented endothelial dysfunction in the kidney of these animals (Oltean et al., 2014). Here we show that a reduction in VEGF-A_{165}b in the lumbar spinal cord of diabetic animals was associated with neuropathic pain and a degeneration of the spinal vasculature. Systemically reintroducing VEGF-A_{165}b prevented vascular degeneration, spinal cord neuron activation and pain. VEGF-A_{165}b was reduced in diabetic rats, despite reports that VEGF-A_{165}b is associated with inhibition of vessel growth (Woolard et al., 2004). Thus VEGF-A_{165}b should be considered both an anti-angiogenic, and an endothelial survival factor—or a homeostatic counterpart to its vascular remodelling isoform, VEGF-A_{165}a. It must be noted that the actions of VEGF-A_{165}b and VEGFR2 on pain may not be restricted to vascular protection but also to effects on the spinal cord neurons, either indirectly, as VEGF-A_{165}b has been shown to inhibit peripheral sensory neuron excitability and activation of peripheral nociceptors induce c-fos expression in the dorsal horn(Hulse et al., 2014), or directly through inhibiting VEGF-A_{165}a actions on spinal cord circuitry (Hulse et al., 2016). Accompanying this, neutralising endogenous VEGF-A_{165}b as well as pharmacological blockade of VEGFR2 signalling at the
level of the spinal cord led to the development of pain (Hulse et al., 2016). In addition, reductions in VEGF-A\textsubscript{165b} expression and no change in total VEGF-A expression would highlight a plausible increase in alternative isoforms such as VEGF-A\textsubscript{165a}, an event associated with pro-nociception and chronic pain (Hulse et al., 2014; Hulse et al., 2016) which cannot be ruled out in this instance.

Furthermore, some consideration does need to be made when using diabetic models such as in the instance of using STZ. STZ is a reliable rodent model of type 1 diabetic neuropathy displaying comparable pain behaviour, nerve electrophysiological parameters and nerve histology, used widely throughout the field of diabetes research. However, it is an experimental model of islet cell ablation by a toxic agent that may have other effects, so despite its widespread use in many experimental models of diabetic complications (nephropathy, neuropathy, retinopathy and others) it is still critical that these findings are reproduced in type II diabetic models, and other models of type I diabetes before being applied to people with diabetes.

These findings lead us to speculate that diabetes induced alterations of the somatosensory systems, for instance by affecting the vasculature supporting somatosensory processing at the level of the spinal cord, could be a key concept in regulating neuropathic pain and treatment of such complications (for example spinal cord vasculopathy) could provide a key target in treating diabetic neuropathic pain.

In summary, we report for the first time a significant vascular degeneration in the spinal cord of diabetic rats, which is associated with a loss of spinal VEGF-A\textsubscript{165b}. This was accompanied by spinal neuron activation, indicative of altered function of the spinal cord neurons, and also by enhanced nociceptive pain behaviour. Administration of VEGF-A\textsubscript{165b} alleviated both the spinal cord vascular degeneration and pain neuropathic pain. This work is complementary to previous work in the nervous system demonstrating a neuroprotective action of VEGF-A (Reeson et al., 2015; Taylor et al., 2015), but herein we demonstrate central effects in the spinal cord with potential contribution to the control of chronic pain development, rather than actions purely at peripheral sites. These findings provide additional avenues for to further understanding diabetic neuropathic pain and the possible mechanisms that underlie sensitisation of nociceptive pathways.
Acknowledgements

NV, RPH, MD, NBL, CV and SMB performed the animal work, the immunofluorescence, cell culture and immunoblotting in the Tumour and Vascular Biology Laboratories at the University of Nottingham. KBH generated the recombinant human VEGF-A_{165b} protein. RPH, NV, NBL, CV, MH, KBH, MD, SMB, LFD & DOB contributed to the conception or design of the work in addition to acquisition, analysis or interpretation of data for the work. RPH, NV, NBL, CV, MH, KBH, MD, SMB, LFD & DOB drafted the work or revised it critically for important intellectual content. RPH drafted the manuscript with contributions from all authors. All authors approved the final version of the manuscript, agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved all persons designated as authors qualify for authorship, and all those who qualify for authorship are listed. We also thank the Flow Cytometry Facility (UoN) and Dr David Onions.

Funding

This work was supported by Diabetes UK (11/0004192 to LFD, and 10/0004152 to DOB), MRC grant MR/K013157/1 to DOB, The Richard Bright VEGF Research Trust (UK Registered Charity 1095785), the European Foundation for the Study of Diabetes Microvascular Programme supported by Novartis to RPH and the Rosetree Trust (A1360) to RPH.

Conflict of Interest

LFD and DOB are co-inventors on patents protecting VEGF-A_{165b} and alternative RNA splicing control for therapeutic application in a number of different conditions. LFD and DOB are founder equity holders in, and DOB is a director of Exonate Ltd, a company with a focus on development of alternative RNA splicing control for therapeutic application in a number of different conditions, including diabetic complications. The authors have no other conflicts of interest to declare.
References


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


Figure 1 – Diabetes-induced neuropathic pain is associated with a reduction in spinal cord vasculature and a decrease in VEGF-A_{165b} expression. [A] Diabetes resulted in a reduction in mechanical withdrawal threshold measured by pincher, when compared with naïve age matched animals (*p<0.05, n=5/group). [B] Blood vessels identified (IB_{4}) in the deeper laminar layers of the spinal cord (layers III-VI) of the naïve animal [C] with a decline in vascular staining in the diabetic animal. [D] There was a reduction in blood vessel (CD31/IB_{4}+ve) number (*p<0.05, n=4/group) [E= naïve, F = Diabetic; reduced diameter (*p<0.05, n=4/group) as well as diameter [G] in the lumbar spinal cord in diabetic animals compared with naïve controls. [H] Immunoblot of panVEGF, VEGF-A_{165b} and actin in lysates from spinal cord of normal and diabetic animals. [I]. Densitometry analysis demonstrates no change in pan-VEGF-A expression and a decrease in VEGF-A_{165b} expression in diabetic lumbar spinal cord versus naïve animals. (*p<0.05, n=5/group) (B&C Scale bar= 40μm, E&F Scale bar= 20μm).
Figure 2 – Diabetes induced vascular impairment in the spinal cord. [A] Isolated spinal cord endothelial cells demonstrated increased cell death in 50mM glucose when compared with 50mM mannitol and 5mM glucose (*p<0.05, ***p<0.001). [A] VEGF-A<sub>165b</sub> treatment prevented high glucose-induced endothelial cell death (**p<0.01). [B] IB<sub>4</sub> stained vasculature in the spinal cord of naïve age matched controls was compared with that in [C] diabetic+vehicle (Arrow heads = vessels smaller than 6µm) and [D] diabetic +VEGFA<sub>165b</sub>. [E] There was a significant reduction in total volume of the microvasculature in the spinal cord of the diabetic+vehicle group in addition to [F] a reduction in vessel diameter compared with naïve controls (**p<0.01, ***p<0.001, n=4/group). [E-F] VEGF-A<sub>165b</sub> treatment prevented the diabetes-induced vascular degeneration in the lumbar spinal cord (**p<0.01, n=4/group). [G] VEGF-A<sub>165b</sub> treatment also prevents the diabetes induced decrease in larger and intermediate microvessels. (B-D Scale bar = 25µm).
Figure 3 – Diabetes induced degeneration of the endothelium. Immunoblots using dual colour far red imaging for endothelial markers ([A] VE-Cadherin, [A] CD31 and [B] occludin and [B] actin) demonstrated [C] a non-significant reduction in VE-cadherin expression and significant reductions in [D] CD31 and [E] occludin in the diabetic+vehicle group compared with naïve and diabetic+VEGF-A165b animals (*p<0.05,n=5).

A

Diabetic  -  +  +  
VEGF-A165b  -  -  +

B

Diabetic  -  +  +  
VEGF-A165b  -  -  +

C

\[
\begin{align*}
\text{VE-CAD/Actin} & \\
\text{Naive} & \ 0.054  \\
+Veh & \ 0.08  \\
+VEGF-A165b & \ 0.15  \\
\text{Diabetic} & \\
\end{align*}
\]

D

\[
\begin{align*}
\text{CD31/Actin} & \\
\text{Naive} & \ 0  \\
+Veh & \ 0  \\
+VEGF-A165b & \ 0  \\
\text{Diabetic} & \\
\end{align*}
\]

E

\[
\begin{align*}
\text{Occludin/Actin} & \\
\text{Naive} & \ 0  \\
+Veh & \ 0  \\
+VEGF-A165b & \ 0  \\
\text{Diabetic} & \\
\end{align*}
\]
Figure 4 – Reduced vascular functionality in the spinal cord of diabetic rats. There was a significant reduction in Evans blue solute flux in the lumbar spinal cord of diabetic animals after [A] 1 week (naïve; n=9, diabetes; n= 12, ***p<0.001) and [B] 8 weeks (*p<0.05, n=4/5 /group). VEGF-A_{165b} treatment prevented the diabetes-induced reduction in solute flux within the lumbar spinal cord at 8 weeks (*p<0.05, n=4/5 /group). [C] There was no change in solute flux in the brain of any treatment group (naïve vs diabetic+vehicle = p=0.52; diabetic+vehicle vs diabetic +VEGF-A_{165b} = p=>0.99; n=4/5 /group).
Figure 5 – Diabetes induced dysfunction of microvasculature in the spinal cord and neuropathic pain is reversed by VEGF-A_165b. [A] Diabetic+vehicle animals demonstrated a decrease in mechanical withdrawal threshold (vF hairs) and [B] reduced withdrawal latency to heat compared with both naïve and diabetic+VEGF-A_165b treated groups (*** p<0.01, ** p<0.001 naïve vs diabetic+vehicle; # p<0.001 diabetic +VEGF-A_165b vs diabetic+vehicle, n=5 per group). Arrow highlight onset of VEGF-A_165b treatment.[C] Cleaved caspase-3 (red=CC3) and sensory neuron (green=NeuN) staining in the spinal cord (Scale bar=40μm). [D] There was an increase in cleaved caspase-3 expression in sensory neurons in the superficial lamina (I&II) of the dorsal horn of the spinal cord in the diabetic + vehicle groups compared with naïve age matched controls and VEGF-A_165b treated diabetic animals. [E] There is an increased number of CC3 positive dorsal horn sensory neurons (arrows in E) in the dorsal horn of the spinal cord in the diabetic + vehicle groups compared with naïve age matched controls and VEGF-A_165b treated diabetic animals. This is graphically represented in [F] (*p<0.05, n=4).
Figure 6 – Diabetes induced hyperactivity in sensory neurons of the dorsal horn in the spinal cord. [A-B] Immunoreactivity of a marker of central sensitisation, c-fos (red; NeuN green), was increased in sensory neurons in the dorsal horn of the spinal cord in diabetic+vehicle animals versus naïve animals. This was reduced by VEGF-A_{165b} treatment. [C] There was an increase of c-fos expression in sensory neurons in all lamina of the dorsal horn (I-V) in the diabetic+vehicle group when compared to naïve and diabetic+VEGF-A_{165b} (*p<0.05, **p<0.001, ***p<0.001; n=4).
Figure 7 – Tamoxifen induced VEGFR2 knockout. VEGFR2 was inducibly knocked out in endothelial cells by crossing *vegfr2*^fl/fl^ with Tie2Cre^ERT2^ mice and treating with tamoxifen (VEGFR2^[ECKO] ). [A] In lung tissue, VEGFR2 protein was detected in tamoxifen treated *vegfr2*^fl/fl^ mice lacking Cre (CTL), but not in VEGFR2^[ECKO] mice [B] Immunoblot densitometry demonstrated reduced VEGFR2 protein in the VEGFR2^[ECKO] mice compared with controls (*p<0.05, n=6 per group). [C-D] VE-cadherin expression was also reduced in lung tissue of the VEGFR2^[ECKO] mice (*p<0.05, n=6 per group). [E] There was a reduction in VEGFR2 in the spinal cord of the VEGFR2^[ECKO] mice when compared to CTL mice (*p<0.05, n=4 per group), this was accompanied by reductions in endothelial markers [F] VE-cadherin and [G] CD31 (**p<0.01, n=4 per group. [H] Western blot of the lumbar spinal cord from VEGFR2^[ECKO] mice demonstrating [I] a reduction in VE-Cadherin expression when compared to CTL mice.
Figure 8 - Inducible endothelial cell vegfr2 KO caused microvasculature loss in the dorsal horn of the lumbar region of the spinal and hyperalgesia. Representative images from the microvessels in [A lower power; B high power] vegfr2\textsuperscript{fl/fl} Tie2Cre\textsuperscript{ERT2} positive mice + vehicle (Vehicle) and [D-F] VEGFR2\textsuperscript{ECKO}. VEGFR2\textsuperscript{ECKO} mice had a significant reduction in microvasculature [C] volume and [D] diameter compared with controls (CTL and vehicle). (**p<0.000, *p<0.01, comparison between Vehicle and CTL vessel diameter p= 0.5391). [E] VEGFR2\textsuperscript{ECKO} mice had an increased number of smaller microvessels versus other experimental groups. [F] VEGFR2\textsuperscript{ECKO} mice showed a reduced withdrawal latency to heat when compared to control mice(****p<0.001 comparison made at day 11 between CTL (p=0.003), Vehicle (P=0.001) and CTL +Vehicle (P=0.0008) against VEGFR2\textsuperscript{ECKO} mice, n=10/11 per group).
Figure 9 – Tamoxifen did not induce a loss in haematopoietic cells in the mouse spleen
[A-B] Cells isolated from mouse spleens were analysed using flow cytometry to identify [C] F4/80 and [D] CD11b cell populations. In VEGFR2^{ECKO} + tamoxifen mice there were no changes in cell number in [E] F4/80 (p=0.630), [F] CD11b (p>0.99) and [G] F4/80/CD11b (p>0.99) cell populations or [H & I] median fluorescent intensity (F4/80=p=0.11; CD11b=0.11) when compared with tamoxifen treated Tie2CRE mice (n=4/group).